Related Experiment Video
Updated: Jul 2, 2026
11:39
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
Published on: October 23, 2019
Pentostatin in chronic lymphocytic leukemia.
Craig Sauter1, Nicole Lamanna, Mark A Weiss
1Leukemia Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Expert Opinion on Drug Metabolism & Toxicology
|August 30, 2008
Summary
Pentostatin offers a safer and more manageable treatment option for chronic lymphocytic leukemia (CLL) compared to fludarabine. This purine analogue shows comparable efficacy with reduced toxicity and easier administration for CLL patients.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Chronic lymphocytic leukemia (CLL) predominantly affects older adults, with current treatments lacking curative potential.
- Standard purine analogue combinations for CLL achieve complete responses but are limited by significant toxicities like myelosuppression and infection risk.
Purpose of the Study:
- To evaluate the role of pentostatin, an adenosine deaminase (ADA) inhibitor, in treating CLL.
- To compare the safety and efficacy of pentostatin against other purine analogues, particularly fludarabine.
- To review pentostatin's applications in other hematologic malignancies.
Main Methods:
- Literature review focusing on the historical treatment of CLL.
- Analysis of modern combination chemoimmunotherapy strategies in CLL.
- Assessment of pentostatin's advantages within therapeutic regimens.
Main Results:
- Pentostatin-based combination therapy demonstrates response rates comparable to fludarabine-based regimens.
- Pentostatin exhibits a more favorable toxicity profile than fludarabine.
- Pentostatin offers simpler administration compared to existing combination therapies.
Conclusions:
- Pentostatin represents a promising therapeutic agent for CLL, offering comparable efficacy with improved safety and tolerability.
- The reduced toxicity and ease of administration make pentostatin a valuable option for CLL management.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...